


Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 ≥50% treated with first line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. Cortellini A, et al.



• Pembro-real 5Y is a global real-world registry including 1050 patients with advanced NSCLC and PD-L1 ≥50%, treated with first-line pembrolizumab.

• The registry compares real-world data with clinical trial outcomes from the Keynote-024 (KN024) trial using individual patient-level data (IPD cohort) from the KN024 and the KN024 «look alike» cohort including only patients who met the KN024 eligibility criteria.

• The overall cohort showed a 5-year survival rate of 26.9%, comparable to the KN024 look-alike cohort (29.3%) and the KN024 IPD cohort (31,9%).

• Conditional inference tree (CIT) analysis identified ECOG-PS, age, and PD-L1 TPS as the main determinants of long-term survival.

• Safety confirmed the profile reported in the KN024 trial, although with immune-related adverse events occurring beyond two years landmark (22.3% any grade, 5.5% grade 3/4).